Fat in liver, not belly, could determine heart disease risk

Washington, Aug 25 (ANI): Measuring liver fat may be a better way to determine a person’s risk for developing diabetes and heart disease than measuring belly fat, according to researchers at Washington University School of Medicine in St. Louis.

Having too much liver fat is known as nonalcoholic fatty liver disease.

The researchers say that when fat collects in the liver, people experience serious metabolic problems such as insulin resistance, which affects the body’s ability to metabolize sugar.

They also have increases in production of fat particles in the liver that are secreted into the bloodstream and increase the level of triglycerides.

For years, scientists have noted that where individuals carried body fat influences their metabolic and cardiovascular risk.

Increased fat inside the belly, known as visceral fat, is linked to an higher risk of diabetes and heart disease.

“Data from a large number of studies shows that visceral fat is associated with metabolic risk, which has led to the belief that visceral fat might even cause metabolic dysfunction,” says study’s lead author Samuel Klein.

“However, visceral fat tracks closely with liver fat. We have found that excess fat in the liver, not visceral fat, is a key marker of metabolic dysfunction. Visceral fat might simply be an innocent bystander that is associated with liver fat,” he added.

Klein says most of our body fat, called subcutaneous fat, is located under our skin, but about 10 percent is present inside the belly, while much smaller amounts are found inside organs such as the liver and muscle.

In the study, the researchers compared obese people with elevated and normal amounts of liver fat. All subjects were matched by age, sex, body mass index; percent body fat and degree of obesity.

Through careful evaluations of obese people with different amounts of visceral fat or liver fat, Klein’s team determined that excess fat inside the liver identifies those individuals who are at risk for metabolic problems.

The study has been published online in the journal PNAS Early Edition. (ANI)

Grapefruit derivative ‘prevents obesity’

Washington, July 14 (ANI): A new study on mice, conducted by University of Western Ontario researchers, has shown that grapefruit contains a substance that’s a natural fat fighter.

Derived from citrus fruit, particularly grapefruit, the substance has shown it can reduce weight gain and fatty particles in the body, Murray Huff of UWO’s Robarts Research Institute said.

The substance, a flavonoid – a bioactive molecule – called naringenin, shows promise as an inhibitor of conditions associated with type 2 diabetes and cardiovascular disease, he said.

In the study, one group of mice was fed a high-fat diet to induce the symptoms of metabolic syndrome. A second group was fed the exact same diet and treated with naringenin.

Naringenin corrected the elevations in triglyceride and cholesterol, prevented the development of insulin resistance and completely normalized glucose metabolism.

The researchers found it worked by genetically reprogramming the liver to burn up excess fat, rather than store it.

“Furthermore, the marked obesity that develops in these mice was completely prevented by naringenin,” said Huff.

“What was unique about the study was that the effects were independent of caloric intake, meaning the mice ate exactly the same amount of food and the same amount of fat. There was no suppression of appetite or decreased food intake, which are often the basis of strategies to reduce weight gain and its metabolic consequences,” Huff added.

This study investigated naringenin’s preventative properties, but Huff is also investigating whether it can treat obesity and other existing metabolic problems.

The findings are published online in the journal Diabetes. (ANI)

Demjanjuk back in jail after treatment for gout

Munich – John Demjanjuk, the 89-year-old man accused of herding Jews to gas chambers at a Nazi death camp in 1943, returned to a German jail on Wednesday after three days of hospital treatment for gout, his lawyer in Munich said.

Guenther Maull said medical tests on Demjanjuk would continue after the course of treatment at Harlaching Hospital in the city.

“They are tests to establish his fitness to stand trial,” said Maull. If he were not fit, there would be no purpose in indicting him. “The prosecutors won’t be able to indict him until after he has been interrogated, or if he is not fit to stand trial,” he said.

Gout is a disease of the joints caused by metabolic problems leading to high levels of uric acid in the blood. It is often triggered by eating unsuitable food. Demjanjuk was moved to the city hospital on Monday.

Demjanjuk was deported to Munich from the United States this month to face charges that he was a Nazi auxiliary during the War and took part in the killings of 29,000 Jews at Sobibor death camp.

The main evidence against him is an SS personnel card.

The German defence lawyer said the medical tests would probably be completed late this week, but there was no sign of when the medical report would be ready. Maull said he did not expect any trial to begin before late September. (dpa)